LUCD vs PATH · rev $4.3M vs P/E 19, rev $1.61B
Lucid Diagnostics Inc (LUCD) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Lucid Diagnostics Inc (LUCD) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported LUCD revenue for 2024-12-31 was $4.3M. Net income was -$45.5M. Revenue was up 79.0% from 2023-12-31 to 2024-12-31. LUCD currently screens at market cap $123.3M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
LUCD currently screens at market cap $123.3M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the LUCD and PATH stock pages for the full models.
Not investment advice.